EMBL Ventures exits cancer-destroying virus developer in €210m trade sale

European life science venture capital firm EMBL Ventures has sealed the €210m sale of ViraTherapeutics to pharmaceutical trade buyer Boehringer Ingelheim after three years in its portfolio.